Testing laboratory
WuXi AppTec
Official corporate site, about page, testing platform page, and locations page reviewed
Testing laboratory profile
Enterprise CRDMO whose Laboratory Testing Division provides integrated CMC, DMPK, toxicology, pharmacology, and bioanalytical services for drug development programs.
- Service tier
- Global pharmaceutical contract research and testing organization
- Capabilities
- Toxicology, DMPK, bioanalytical services, CMC testing, and pharmacology integrated into discovery-through-IND development packages. A peptide-specific retail or research-sample testing page was not found in this review.
- Community notes
- Community reports were excluded from this capability record; profile is based on official corporate pages.
Strengths
- Global operations across Asia, Europe, and North America with 34,000+ employees
- Integrated testing platform spanning discovery to IND and beyond
- Multiple U.S. laboratory and manufacturing sites
Limitations
- Peptide-specific sample acceptance, pricing, and turnaround for small or individual clients were not established
- Enterprise engagement model may not fit individual or research-sample submissions
- Accreditation scope is program- and facility-specific and was not normalized in this review
Editorial record
WuXi AppTec is a global CRDMO founded in 2000 with 34,000+ employees serving customers in over 30 countries. Its WuXi Testing division (Laboratory Testing Division) integrates CMC, pharmacology, DMPK, toxicology, and bioanalytical services supporting programs from discovery through IND and beyond. The locations page lists U.S. sites including Cranbury NJ (DMPK and pre-clinical), San Diego CA (biology and WuXi STA small molecule R&D and manufacturing), Natick MA (screening and assay), and Middletown DE (drug product and drug substance manufacturing). This is an enterprise pharmaceutical testing platform, not a consumer or research-peptide sample testing service.
Profile ownership: unclaimed. Company representatives will be able to propose identity and catalog updates without changing editorial or regulatory records.